The Cheshire and Merseyside Area Prescribing Group recommends DAPAGLIFLOZIN and EMPAGLIFLOZIN as options for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults, following specialist recommendation, in accordance with NICE TA902 and TA929.
